Matches in SemOpenAlex for { <https://semopenalex.org/work/W4244967323> ?p ?o ?g. }
- W4244967323 abstract "Cystic fibrosis is an autosomal recessive multisystem disorder with an approximate prevalence of 1 in 3500 live births. Allergic bronchopulmonary aspergillosis is a lung disease caused by aspergillus-induced hypersensitivity with a prevalence of 2% to 15% in people with cystic fibrosis. The mainstay of treatment includes corticosteroids and itraconazole. The treatment with corticosteroids for prolonged periods of time, or repeatedly for exacerbations of allergic bronchopulmonary aspergillosis, may lead to many adverse effects. The monoclonal anti-IgE antibody, omalizumab, has improved asthma control in severely allergic asthmatics. The drug is given as a subcutaneous injection every two to four weeks. Since allergic bronchopulmonary aspergillosis is also a condition resulting from hypersensitivity to specific allergens, as in asthma, it may be a candidate for therapy using anti-IgE antibodies. Therefore, anti-IgE therapy, using agents like omalizumab, may be a potential therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis. This is an updated version of the review.To evaluate the efficacy and adverse effects of anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.We searched the Cochrane Cystic Fibrosis Trials Register, compiled from electronic database searches and handsearching of journals and conference abstract books. We also searched the reference lists of relevant articles and reviews. Last search: 09 September 2021. We searched two ongoing trial registries (Clinicaltrials.gov and the WHO trials platform). Date of latest search: 16 August 2021.Randomized and quasi-randomized controlled trials comparing anti-IgE therapy to placebo or other therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis.Two review authors independently extracted data and assessed the risk of bias in the included study. They planned to perform data analysis using Review Manager.Only one study enrolling 14 participants was eligible for inclusion in the review. The double-blind study compared a daily dose of 600 mg omalizumab or placebo along with twice daily itraconazole and oral corticosteroids, with a maximum daily dose of 400 mg. Treatment lasted six months but the study was terminated prematurely and complete data were not available. We contacted the study investigator and were told that the study was terminated due to the inability to recruit participants into the study despite all reasonable attempts. One or more serious side effects were encountered in six out of nine (66.67%) and one out of five (20%) participants in omalizumab group and placebo group respectively.There is lack of evidence for the efficacy and safety of anti-IgE (omalizumab) therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis. There is a need for large prospective randomized controlled studies of anti-IgE therapy in people with cystic fibrosis and allergic bronchopulmonary aspergillosis with both clinical and laboratory outcome measures such as steroid requirement, allergic bronchopulmonary aspergillosis exacerbations and lung function." @default.
- W4244967323 created "2022-05-12" @default.
- W4244967323 creator A5004241031 @default.
- W4244967323 creator A5068442122 @default.
- W4244967323 creator A5070995955 @default.
- W4244967323 date "2021-09-22" @default.
- W4244967323 modified "2023-09-26" @default.
- W4244967323 title "Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis" @default.
- W4244967323 cites W1493815102 @default.
- W4244967323 cites W1501757022 @default.
- W4244967323 cites W172222733 @default.
- W4244967323 cites W1951252417 @default.
- W4244967323 cites W1985927542 @default.
- W4244967323 cites W1989823290 @default.
- W4244967323 cites W1994490159 @default.
- W4244967323 cites W1996739651 @default.
- W4244967323 cites W1997855218 @default.
- W4244967323 cites W2006205245 @default.
- W4244967323 cites W2009376119 @default.
- W4244967323 cites W2016480485 @default.
- W4244967323 cites W2024931925 @default.
- W4244967323 cites W2039720197 @default.
- W4244967323 cites W2053477586 @default.
- W4244967323 cites W2059474954 @default.
- W4244967323 cites W2062137132 @default.
- W4244967323 cites W2065071227 @default.
- W4244967323 cites W2088624642 @default.
- W4244967323 cites W2097981132 @default.
- W4244967323 cites W2115511578 @default.
- W4244967323 cites W2120901603 @default.
- W4244967323 cites W2121500558 @default.
- W4244967323 cites W2129228230 @default.
- W4244967323 cites W2136496779 @default.
- W4244967323 cites W2151891905 @default.
- W4244967323 cites W2152398817 @default.
- W4244967323 cites W2222064848 @default.
- W4244967323 cites W224916579 @default.
- W4244967323 cites W2260747993 @default.
- W4244967323 cites W2528532333 @default.
- W4244967323 cites W2767394445 @default.
- W4244967323 cites W2949005071 @default.
- W4244967323 cites W2969204814 @default.
- W4244967323 cites W4211151481 @default.
- W4244967323 cites W4240137910 @default.
- W4244967323 cites W4240236213 @default.
- W4244967323 cites W4241884576 @default.
- W4244967323 cites W4242044641 @default.
- W4244967323 cites W4297852198 @default.
- W4244967323 doi "https://doi.org/10.1002/14651858.cd010288.pub5" @default.
- W4244967323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34550603" @default.
- W4244967323 hasPublicationYear "2021" @default.
- W4244967323 type Work @default.
- W4244967323 citedByCount "2" @default.
- W4244967323 countsByYear W42449673232023 @default.
- W4244967323 crossrefType "journal-article" @default.
- W4244967323 hasAuthorship W4244967323A5004241031 @default.
- W4244967323 hasAuthorship W4244967323A5068442122 @default.
- W4244967323 hasAuthorship W4244967323A5070995955 @default.
- W4244967323 hasBestOaLocation W42449673232 @default.
- W4244967323 hasConcept C126322002 @default.
- W4244967323 hasConcept C141105273 @default.
- W4244967323 hasConcept C159654299 @default.
- W4244967323 hasConcept C16005928 @default.
- W4244967323 hasConcept C177713679 @default.
- W4244967323 hasConcept C187212893 @default.
- W4244967323 hasConcept C197934379 @default.
- W4244967323 hasConcept C203014093 @default.
- W4244967323 hasConcept C2776042228 @default.
- W4244967323 hasConcept C2776391196 @default.
- W4244967323 hasConcept C2776938444 @default.
- W4244967323 hasConcept C2777071850 @default.
- W4244967323 hasConcept C2778564945 @default.
- W4244967323 hasConcept C2778871687 @default.
- W4244967323 hasConcept C2779548794 @default.
- W4244967323 hasConcept C71924100 @default.
- W4244967323 hasConceptScore W4244967323C126322002 @default.
- W4244967323 hasConceptScore W4244967323C141105273 @default.
- W4244967323 hasConceptScore W4244967323C159654299 @default.
- W4244967323 hasConceptScore W4244967323C16005928 @default.
- W4244967323 hasConceptScore W4244967323C177713679 @default.
- W4244967323 hasConceptScore W4244967323C187212893 @default.
- W4244967323 hasConceptScore W4244967323C197934379 @default.
- W4244967323 hasConceptScore W4244967323C203014093 @default.
- W4244967323 hasConceptScore W4244967323C2776042228 @default.
- W4244967323 hasConceptScore W4244967323C2776391196 @default.
- W4244967323 hasConceptScore W4244967323C2776938444 @default.
- W4244967323 hasConceptScore W4244967323C2777071850 @default.
- W4244967323 hasConceptScore W4244967323C2778564945 @default.
- W4244967323 hasConceptScore W4244967323C2778871687 @default.
- W4244967323 hasConceptScore W4244967323C2779548794 @default.
- W4244967323 hasConceptScore W4244967323C71924100 @default.
- W4244967323 hasIssue "9" @default.
- W4244967323 hasLocation W42449673231 @default.
- W4244967323 hasLocation W42449673232 @default.
- W4244967323 hasLocation W42449673233 @default.
- W4244967323 hasOpenAccess W4244967323 @default.
- W4244967323 hasPrimaryLocation W42449673231 @default.
- W4244967323 hasRelatedWork W1968390294 @default.
- W4244967323 hasRelatedWork W1989823290 @default.
- W4244967323 hasRelatedWork W2058194605 @default.